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Abstract 
In most countries CD4+ cell counts are still used for deciding when to start HIV-positive people on anti-retroviral 
therapy. However, various CD4+ thresholds, 200, 350 or 500/μL, are chosen arbitrarily and for historical reasons. Here 
we consider the optimal CD4+ threshold at which asymptomatic HIV-positive people living in Botswana, South Africa 
and Zimbabwe should start treatment depending on their prognosis given their CD4+ cell counts or viral load. We also 
examine the optimal interval at which people should be retested if they are HIV-negative. This analysis shows that 
while the use of CD4+ cell counts or viral load tests could have been useful in deciding how to triage patients for 
treatment at the start of the epidemic this is no longer the case except possibly for those aged about 15 to 25 years. In 
order not to do harm to individual patients everyone should be started on ART as soon as they are found to be HIV-
positive. 
Introduction 
Deciding when to start anti-retroviral therapy is 
important both for the prognosis of the individual 
patient and to prevent transmission. In this paper we are 
concerned only with the prognosis for asymptomatic, 
HIV-positive people (WHO clinical stage I1,2); we 
assume that all those with AIDS defining infections or 
conditions, (WHO clinical stages II to IV1,2) should start 
anti-retroviral therapy (ART) immediately. 
 In 1996 triple-drug therapy became available3,4 and 
was shown to reduce plasma viral load by two orders of 
magnitude5 but the annual cost per person for first-line 
triple-drug therapy in Africa was US$12k6 and some of 
the drugs gave rise to serious side effects. Nevertheless, 
in 1996 the International AIDS Society (IAS) 
recommended giving ART to all patients with a CD4+ 
cell count below 500/μL or a viral load greater than 
30k/mL.4 In 1997 the IAS dropped the CD4+ condition 
but lowered the viral load threshold to 5k/mL. They 
noted that a decision to initiate therapy at CD4+ cell 
counts above 500/μL should be tempered by the 
potential problems related to long-term toxicity, 
tolerance, acceptance, cost, and the development of drug 
resistance.4 Nevertheless, it was clear that early 
initiation of anti-retroviral therapy (ART) had 
virological, immunological and clinical benefits4 and 
the IAS maintained their recommendations for starting 
ART, with slight variations, until the year 2000.7-9 In the 
year 2000 the IAS reintroduced the CD4+ threshold at 
350/μL and maintained the viral load cut-off at 5k/mL.  
 In 2002 there was an important shift towards 
delaying treatment because some key drugs were poorly 
tolerated leading the IAS to lower the CD4+ threshold 
and raise the viral load threshold. ART was now 
recommended for those with a CD4+ cell count less 
than 200/μL or a viral load greater than 50k/mL to 
100k/mL.10 
 At about the same time the World Health 
Organization (WHO), in collaboration with the United 
States National Institutes of Health, convened 
consultative meetings in which more than two hundred 
clinicians, scientists, government representatives, 
representatives of civil society and people living with 
HIV/AIDS from more than sixty countries 
participated.11 The recommendations noted that while 
starting therapy at CD4 cell counts above 200/μL 
clearly provides clinical benefits, the actual point above 
200/μL at which to start therapy had not been 
definitively determined.11 For reasons that are not made 
explicit in the published guidelines11 WHO 
recommended that treatment should be given only to 
people with a CD4+ cell count below 200/μL, in 
agreement with the IAS recommendations. Because 
viral load testing was not generally available in resource 
limited settings, the viral load condition was not 
included. In 2003 WHO revised their guidelines slightly 
upwards and suggested using CD4 cell counts between 
200/μL and 350/μL to assist decision-making for those 
in WHO clinical stages III or IV.12 In 2007 WHO 
published a further revision13 in which they said that at a 
CD4+ cell count below 200/μL treatment should be 
started immediately, between 200/μL and 350/μL 
treatment should be considered while taking into 
account clinical staging, and that above 350/μL 
treatment should not be started. 
 Following a review and synthesis of new evidence 
the World Health Organization revised their guidelines 
in 2009 to recommend starting people on ART if their 
CD4+ cell count is less than 350/μL.14,15  
 In 2010 the IAS once again recommended ART for 
all HIV-positive people with a CD4+ cell count below 
500/μL, without excluding treatment for those with a 
higher cell count, or a viral load above 100k/mL.16 In 
2012 the IAS recommended ART for all HIV-positive 
people.17 
 By 2001 the annual cost of triple drug therapy had 
dropped form US$12k to less than US$1k and the price 
of drugs has continued to fall6,18 with generic 
formulations available in 2012 for US$150 per year.18 
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The new drugs are easier to tolerate and have few 
serious side effects.  
 In order to make the implications of the various 
changes in recommendations clear we use CD4+ and 
plasma viral load data from a cross-sectional study of 
young men in Orange Farm, South Africa, in 200219,20 
to estimate the proportion that would have been eligible 
for treatment under the different, changing, 
recommendations. The results are shown in Figure 1. 
 
 
 
 
 
 
 
 
 
Figure 1. The proportion of young men in Orange Farm, South 
Africa, who would had to have started treatment in 2002 as the 
treatment guidelines changed over time. Blue: IAS; red: 
WHO; green current practice in different numbers of 
countries. Error bars reflect the sample size in the Orange 
Farm data. 
 Using the 19 96 IAS guidelines4 (CD4+ cut-off: 
500/μL; viral load cut-off: 30k/mL), 72% (66%−79%) 
of all HIV-positive men in Orange Farm in 2002 should 
have started ART. Under the 1997 IAS guidelines8 
(viral load cut-off: 5k/mL), the proportion needing to 
start treatment would have increased to 86% 
(81%−90%)  and under the 2000 IAS guidelines6 (CD4+ 
cut-off: 500/μL; viral load cut-off: 5k/mL) would have 
increased further to 89% (84%−93%). The 2002 IAS 
guidelines10 (CD4+ cut-off: 200/μL; viral load cut-off: 
50k/mL) were more conservative and the proportion 
needing to start treatment would have fallen to 53% 
(46%−60%). The 2002 WHO guidelines were 
considerably more conservative11 (CD4+ cut-off: 
200/μL) because they did not include a viral load 
criterion and the proportion of people eligible for ART 
would have dropped dramatically to only 10% 
(6%−15%) of those living with HIV. The 200312 and 
200713 WHO guidelines remained the same for 
asymptomatic people while the 2009 WHO 
guidelines14,15 were a little more aggressive (CD4+ cut-
off: 350/μL) and the proportion needing treatment 
would have increased to 29% (22%−35%). The 2010 
IAS guidelines16 (CD4+ cut-off: 500/ml; viral load cut-
off 100k/mL) would have increased this further to 62% 
(55%−69%) and finally the 2012 IAS guidelines17 
recommend immediate treatment for all HIV-positive 
people. 
 In practice the guidelines for when to start treatment 
now vary greatly by country as indicated by the green 
dots in Figure 1.21 In the United States of America the 
advice is to start ART immediately, irrespective of 
CD4+ cell count. Three countries recommend starting 
ART at a CD4+ cell count at or below 500/μL, 40 
recommend starting ART at a CD4+ cell count at or 
below 350/μL and in 3 a threshold of 500/μL may also 
be considered. In 5 countries ART initiation is only 
recommended for those with a CD4+ cell count below 
250/μL and in 20 countries below 200/μL.21 
 While several studies have shown that the earlier 
HIV-positive people start treatment the better is their 
prognosis22-30 this has not been fully examined in 
relation to the CD4+ cell count or the viral load at 
which people start ART. There is still a need to provide 
a rational basis for deciding on when people should start 
ART if their CD4+ cell counts or viral load are known 
and for deciding how often people should return to be 
tested if they are HIV-negative. In this paper we 
consider the prognostic value of CD4+ cell counts and 
plasma viral load in relation to the likely survival of a 
person infected with HIV in three African countries. 
 ART can reduce the viral load in people infected 
with HIV by up to 10,000 times,31-33 and this can be 
sustained for at least seven years31,32 and probably 
indefinitely. It therefore follows that annual testing and 
immediate ART can stop transmission of HIV.33-38 
However, it is important to ensure that public health 
benefits to the wider community are not gained at the 
expense of significant harm to individual patients. Here 
we do not consider the broader public health benefits 
that may accrue from early treatment of HIV-positive 
people34,36,39 but focus on what is in the best interests of 
the individual patient. 
Methods 
It is important for countries to decide on sensible 
criteria for starting people on ART. Here we suggest 
that this should be based on the assumption that where 
resources are limited we need to prioritise those people 
that are most likely to die soon. In an ideal world one 
would simply rank people in order of their predicted life 
expectancy and then start from those with the shortest 
life-expectancy and progressively include people with 
longer and longer life expectancies until the supply of 
drugs is exhausted. In practice we cannot do this 
because we do not have complete information on all 
HIV-positive people at a given time and indeed some 
people will be found to have HIV while they are still 
healthy while others will only be found to have HIV 
when they are close to death. 
 We therefore suggest that the most efficient way to 
triage patients for ART should be to give priority to 
those most likely to die within a specified time, given 
all of the information that we are able to collect at the 
time that the person is diagnosed. More precisely we 
will say that people should be started on ART if their 
chance of dying in a time τ∗ is greater than some pre-
determined probability π∗. If we were to choose people 
at random then, since the mean life expectancy after 
infection without ART would be about ten years, the 
average annual mortality would be about 10% and 
people would, on average, have a 10% probability of 
dying in the next one year. In order to identify those 
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who have a greater than average chance of dying in the 
next  one year we might say that if a person is found to 
be HIV-positive and has a greater than π∗ = 5% chance 
of dying in the next τ∗ = 1 year then they should be 
started on ART. The values of τ∗ and π∗ can be chosen 
according to the affordability and availability of the 
drugs. Any person who is not started on treatment 
immediately and develops an AIDS related condition 
should start treatment immediately. Having decided on 
appropriate values of τ∗ and π∗ we can then decide on 
the CD4+ cell count or the viral load at which to start 
people on ART. 
 In deciding on the CD4+ count at which people 
should start on treatment we need to take into account 
the fact that CD4+ cell counts are known to vary widely 
within and among different populations of HIV-negative 
people,20,40-47 between men and women,40,48 for many 
other reasons,49-51 and with the stage of the epidemic.20  
 In deciding on the viral load at which people should 
be started on treatment we need to allow for the fact that 
set-point viral loads, the value of the viral load at which 
it reaches a more or less stable value after the acute 
phase of infection, varies widely within populations of 
HIV-positive people,19 and is a good predictor of life 
expectancy after sero-conversion and without access to 
ART.52,53 
 Finally, to decide on how frequently people should 
be tested we need to know the incidence of HIV which 
will depend on age, gender, the population at risk and 
the stage of the epidemic.54 
Data 
In this study we draw on a wide range of data including 
the age of the person, the time course of the epidemic in 
the country under consideration and the age and gender 
specific incidence of infection. We use data on the 
distribution of survival as a function of viral load, on the 
distribution of CD4+ cell counts in HIV-negative people 
and the distribution of the set-point viral load in HIV-
positive people. We use data on the relationship 
between the set-point viral load and survival. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Probability of survival as a function of age at 
infection.55 Right (pink) to left (blue) to lines: infected at 0−5, 
5−15, 15−25, 25−35, 35−45, 45−55, 55−65, 65+ years. Fits are 
Weibull probabilities with shape parameter 2.18 ± 0.14. 
Median survival given in Figure 3. 
 Survival after infection is highly variable within and 
between different age groups and the best data are from 
the CASCADE study55 shown in Figure 2. The data can 
be fitted to Weibull survival curves across all age-
groups keeping the shape parameter fixed at 2.18 ± 0.14 
and allowing the median survival to vary among age-
groups. A shape parameter of 2.18 suggests that the 
survival probability is close to Gaussian and that 
mortality increases almost linearly with time since 
infection. 
 From the fits to the data in Figure 2 we can 
determine the relationship between the median survival 
and the age at infection and this is shown in Figure 3. 
The median survival for a person infected at the age of 
30 years is 11.8 years falling linearly from about 16 
years for those infected at the age of 5 years, to 5 years 
for those infected at the age of 65 years. 
 The distribution of CD4+ cell counts varies both 
within and among countries. We use data shown in 
Figure 4 for Botswana,56 Zimbabwe46 and South 
Africa.20 For Botswana and Zimbabwe we fitted the data 
to the published median and inter-quartile ranges57 and 
for South Africa we used the raw data.20 
 
 
 
 
 
 
 
 
 
 
Figure 3. Median life expectancy as a function of the age at 
infection from the fits to the data in Figure 2. The slope of the 
line is −0.188 ± 0.008; the value at age 30 years is 11.76 ± 
0.18 years. 
 
 
 
 
 
 
 
 
 
 
Figure 4. Probability density functions for CD4+ cell counts. 
Green: Botswana;56 Red: Zimbabwe;46 Blue: South Africa.20 
Fitted curves are log-normal distributions with mean m and 
shape parameter s. Botswana m = 726/μL, s = 0.33; 
Zimbabwe m = 838/μL, s = 0.32; South Africa m = 
1116/μL, s = 0.33. 
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 The distribution of viral load in a cross-sectional 
survey of young men in Orange Farm, South Africa is 
given in Figure 519 and, in the absence of other data we 
take this to represent the distribution of viral load in all 
of the countries under consideration. Strictly speaking 
we should use the distribution of set-point viral loads 
and the data in Figure 5 will be biased by the shorter life 
expectancy of people with high set-point viral loads, as 
illustrated in Figure 6, and also by the time course of the 
epidemic. 
 
 
 
 
 
 
 
 
 
 
Figure 5. Probability density of viral load as a function of the 
log-viral load for young men in Orange Farm, South Africa.19 
 The prevalence and incidence of infection over time 
are shown in Figure 7 and Figure 8, respectively, for 
Botswana, Zimbabwe and South Africa. These estimates 
were obtained by fitting a standard SI model, fully 
described elsewhere, to UNAIDS estimates of the 
prevalence of HIV over time.25  The incidence peaked 
earlier and at a higher level in Zimbabwe than in either 
Botswana or South Africa but since 1994 has been 
falling rapidly.58 
 
 
 
 
 
 
 
 
 
Figure 6. The time from infection to death for 16 individuals 
plotted as a function of their set-point viral load.59 The mean 
value of the survival is 6.52 ± 0.31 years and the slope of the 
line is −0.419 ± 0.066 so that for each ten-fold decline in viral 
load survival increases by a factor of 100.419 = 2.62 ± 0.40. 
Baeten et al. obtained a slope of −0.32 ± 0.25.60 
 The age-specific prevalence of infection for women 
attending ante-natal clinics in South Africa in 2010 is 
shown in Figure 9.61 Across a number of studies in 
South Africa it has been shown that distribution of the 
age-specific prevalence does not vary greatly in 
different populations and over time54 and we take this to 
represent the age-specific prevalence in all three 
countries at all times.  
 
 
 
 
 
 
 
 
 
 
Figure 7. Prevalence of HIV infection in adults aged 15+ 
years. Red: Zimbabwe; Green: Botswana; Blue: South Africa. 
Estimates obtained by fitting an SI model, described 
elsewhere, to UNAIDS estimates of the prevalence of HIV 
over time.25 Heavy lines: total prevalence; light lines: 
prevalence of those not on ART. 
 
 
 
 
 
 
 
 
 
 
Figure 8. Incidence of HIV infection in adults aged 15+ years. 
Red: Zimbabwe; Green: Botswana; Blue: South Africa. 
Estimates obtained by fitting an SI model, described 
elsewhere, to UNAIDS estimates of the prevalence of HIV 
over time.25  
 
 
 
 
 
 
 
 
 
Figure 9. Age specific prevalence of infection for women 
attending ANC clinics in South Africa in 2010.61 The fitted 
curve is a log-normal distribution, off-set by 10 years, a 
location parameter of 34.9 years and a scale parameter of 
0.369. 
 From the age specific prevalence and the time-trends 
in the overall prevalence we are able to estimate the 
age-specific incidence.62 We use the incidence estimated 
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in this way for men and women in Carletonville, South 
Africa54 to represent the age specific incidence in all 
three countries at all times as shown in Figure 10. We 
scale this to match the overall incidence shown in 
Figure 8 for each country. 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 10. Age specific incidence of infection for women 
attending ANC clinics in South Africa in 2010. Calculated62 
using data54 from Carletonville, South Africa. 
 There are two key distributions in the model: the 
probability distribution of the time for which a person 
found to be HIV-positive in a cross-sectional survey has 
already been infected and the probability distribution of 
a person’s life-expectancy, given the length of time for 
which they have been infected when they are found to 
be HIV-positive.  
 To calculate the probability density of the time since 
infection, shown in Figure 11, we proceed as follows. 
Let annual the incidence of HIV at time t and age a be 
I(t,a), the probability of surviving for t years, given that 
they were infected at age a, be S(t,a),62 and the 
probability that they start ART between time t1 and t2 
be A(t2,t1). Then the probability that a person was 
infected at time t −τ , is still alive and not on ART, 
ART , at time t, which we shall call R(τ,t), is 
  1 
Then since  
  2 
we can treat this as a normalization factor, N. Then 
  3 
We note firstly that I(t,a) is the incidence per person, 
not per susceptible person, and secondly that  
 
  4 
where IA(t) is the rate at which people start ART, QA(t) 
is the proportion of HIV-positive people who are not on 
ART and PA(t) the proportion who are on ART.† Figure 
11 show the estimate values of R(τ,2010) for women in 
South Africa aged 20, 25, 30 45, 60 and 70 years. 
 In Figure 11 the curve for 20 year-old women is 
sharply peaked at the origin. Because women only 
become sexually active at a median age of 16 years,63 
any 20 year old women who are HIV-positive must 
have been recently infected. The curve for 70 year old 
women is also concentrated near the origin because 
older people have a very short life-expectancy after 
infection (Figure 3) so they too are more likely to have 
been infected recently. It is important to remember that 
while 25 year-old women and 70 year old-women have 
a very similar distribution of the time since they were 
infected, their life expectancies when found to be HIV-
positive are very different. 
  
 
 
 
 
 
 
 
 
 
Figure 11. Probability density of time since infection, R(t), 
for women in South Africa, not on ART, aged 20, 25, 30, 
45, 60 and 70 years of age in 2010. Coloured numbers in 
the chart give the age at which the person is tested for HIV 
for the corresponding line. 
Model 
The model is constructed as follows. We assume that a 
person of a given age and gender is tested for HIV in a 
given country and in a given year. We first calculate the 
probability density of the time since they were infected 
as descried in the data section and illustrated in Figure 
11. This depends on the incidence of infection over time 
since they were more likely to be infected when the 
incidence was high than when it was low (Figure 8); on 
the age-specific incidence of infection since they were 
more likely to be infected between the ages of 25 and 30 
years than at younger or older ages (Figure 10); on their 
survival as a function of their age at infection since 
                                                          
†  This approximation does not account for the number of people that 
become newly infected with HIV or that die before starting ART. 
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older people are more likely to have died before being 
tested (Figure 3); and on the proportion of HIV-positive 
people who are on ART (Figure 7) since if they have 
already started ART they do not need to start again. 
Having calculated the probability density of the time 
since they were infected, we choose a random value, R, 
from this distribution. 
 We then use the known distribution of survival as a 
function of their age at infection (Figure 2 and Figure 3) 
and we choose a random value, S, from this distribution. 
 Finally we obtain a value for their CD4+ cell count 
when they are tested. To do this we choose a random 
value from the CD4+ cell count distribution of people in 
that country, C, reduce it by 25% to allow for the impact 
of the acute phase,20 and assume that after the acute 
phase their CD4+ cell counts decline linearly to death if 
they are not treated. From the values of R, S and C, it is 
a trivial matter to calculate the corresponding value of 
the CD4+ cell count when they are tested for HIV. 
 We then repeat the process very many times, 
typically 105 to 106 times, to determine the probability 
density of their life-expectancy, if they are not treated, 
as a function of their CD4+ cell count when they are 
tested. 
 Finally, we calculate the CD4+ cell count at which 
the probability of dying in the next τ∗ years is greater 
than π∗ and this gives the optimal CD4+ cell count at 
which to start treatment for people of a given age in a 
given country in a given year. 
 We carry out essentially the same exercise assuming 
that we know their viral load rather than their CD4+ cell 
count. To do this we need a model for survival as a 
function of viral load but there is an important, 
unresolved question about which we have to make an 
assumption. We know that viral load and age are both 
good predictors of survival after infection with HIV 
(Figure 3 and Figure 6). What is not known is whether 
or not these factors are independent or correlated. In the 
absence of better data we have two choices: a) we can 
assume that the set-point viral load increases with age 
and that this explains the dependence of survival on the 
age at infection, or b) we can assume that the set-point 
viral load does not change with age at infection so that 
survival depends on both set-point viral load and age at 
infection. Data on survival as a function of viral load are 
sparse and such studies can no longer be repeated given 
the availability of ART. However, it should be possible 
to obtain data on the distribution of the set-point viral 
load as a function of the age at infection and this might 
clarify the situation. 
 In this study we follow the first of the two 
assumptions in the previous paragraph and scale the 
initial distribution of viral load (Figure 5) so that the 
expected survival for the mean value (Figure 6) is equal 
to the expected survival for that age (Figure 3). The 
alternative, the second of the two assumptions in the 
previous paragraph, which we have not explored here 
would be to assume that the set-point viral load is 
independent of age at infection and then allow the 
distribution of survival as a function of viral load to 
shift to shorter survival times as the age at infection 
increases. 
 Using the model we also calculate the proportion of 
people that would have died within one year if they had 
not started ART, the coverage of ART, that is to say the 
proportion of people in each age group that would need 
to start ART under the conditions specified, and the 
reduction in transmission as a result of people starting 
ART. We note that the reduction in transmission is 
calculated as the time between starting treatment and 
death divided by the time between infection and death if 
treatment had not been provided. This does not allow 
for the fact that people with high viral loads are more 
infectious than those with low viral loads.64 
 Finally, we consider the frequency with which 
people should be retested. To do this we calculate the 
time it would take for them to be infected with HIV 
with a probability of 5% using the current incidence of 
HIV (Figure 8), the age specific incidence of HIV 
Figure 10) and their age. Note that we assume that the 
incidence of infection is constant rather than decreasing 
over time so that these estimates will be lower bounds. 
Results 
We first consider what would have been the most 
appropriate CD4+ cell count at which to start ART if the 
drugs had been available in 1990 as shown in Figure 12 
(top graph). In the youngest age group those in 
Botswana should have started ART if their CD4+ cell 
count was below 350/μL while those in South Africa 
should have started when their CD4+ cell count was 
below 550/μL. The CD4+ cell count at which people 
should have started treatment increases slowly up to the 
age of about 40 years (South Africa) and 50 years 
(Botswana) but all those aged above 50 years should 
have started treatment immediately. 
 The key point to note is that in all three countries, 
but especially South Africa, the epidemic was relatively 
young in 1990 so that young people, who had only 
recently become sexually active, must have been 
recently infected. The difference between the CD4+ cut-
off in Botswana and South Africa reflects the substantial 
difference in the CD4+ cell counts in the two countries. 
Since life-expectancy, after infection falls with age, 
older people need to start earlier, and therefore at higher 
CD4+ cell counts, than younger people.  
 If we now consider the situation in the year 2000 as 
shown in Figure 12, middle graph, the criterion for the 
youngest age group remains unchanged since they had 
to have been very recently infected. Older people, who 
have been sexually active for longer, are more likely to 
have been infected for longer (Figure 8), and are 
therefore more likely to die sooner. In all three countries 
everyone above the age of 30 to 35 years should have 
started ART immediately on diagnosis. The situation in 
2010 is similar to that in 2000 but with the age at which 
everyone should have been started on ART shifted to 
younger ages. 
 The proportion of people who would have died 
within one year without treatment (brown text above 
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each graph in Figure 12) is, by definition, 5% if the 
CD4+ criterion is used but once immediate treatment is 
recommend the proportion that would have died without 
treatment increases with age to between 10% and 20% 
at age 70 years. The coverage, that is to say the 
proportion of people who test positive and need to start 
treatment at each age (violet text above each graph in 
Figure 12) increases from about 30% in the youngest 
age group to 100% in the oldest. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. The CD4+ cell count at which people who are 
tested randomly and found to be HIV-positive should start 
ART, as a function of their age, if they are to have a 95% 
chance of surviving for more than one year without it. 
From top to bottom: testing done in 1990, 2000 and 2010. 
Data shown for Botswana, South Africa and Botswana. 
The numbers above each graph are: Brown: the proportion 
that will be expected to die within one year, without 
treatment, if people only start ART at the indicated CD4+ 
cell count; Violet: the proportion of all those testing 
positive who would be started on ART; Red: the amount 
by which transmission would be reduced if people only 
start ART at the indicated CD4+ cell count. Numbers 
above graphs are averages over all three countries. 
 The reduction in transmission, that is to say the 
proportion by which  their infectious period is reduced 
because they are put onto ART  (orange text above each 
graph in Figure 12), increases from about 15% in the 
youngest age group to between 50% and 70% in the 
oldest age groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. The CD4+ cell count at which people who are 
tested randomly and found to be HIV-positive should start 
ART, as a function of their age, if they are to have a 95% 
chance of surviving for more than one year without it. 
From top to bottom: testing done in 1990, 2000 and 2010. 
Data shown for Botswana, South Africa and Botswana. 
The numbers above each graph are: Brown: the proportion 
that will be expected to die within one year, without 
treatment, if people only start ART at the indicated CD4+ 
cell count; Violet: the proportion of all those testing 
positive who would be started on ART; Red: the amount 
by which transmission would be reduced if people only 
start ART at the indicated CD4+ cell count. Numbers 
above graphs are averages over all three countries. 
 The proportion of people who would have died 
within one year without treatment (brown text above 
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each graph in Figure 13) is, again by definition, 5% if 
the CD4+ criterion is used but once immediate 
treatment is recommend the proportion that would have 
died without treatment increases with age to between 
10% and 20% at age 70 years.  
 The coverage, that is to say the proportion of people 
who test positive and need to start treatment at each age 
(violet text above each graph in Figure 12) increases 
from about 30% in the youngest age group to 100% in 
the oldest. 
 
 
 
 
 
 
 
 
 
 
Figure 14. The time at which a person should be asked to 
return for testing if they are found to be HIV-negative as a 
function of age in South Africa and Zimbabwe.  
  The reduction in transmission, calculated as the 
proportion by which their infectious period is reduced 
because they are put onto ART (orange text above each 
graph in Figure 12), is between about 30% and 40% in 
the youngest age group but increases to between 70% 
and almost 100% in the oldest age groups. 
 Figure 13 shows how soon a person should be asked 
to return for testing as a function of their age when 
tested if they are found to be HIV-negative. In South 
Africa people between the ages of about 20 and 38 years 
should be asked to come back for testing after one year; 
people between the ages of 16 to 20 years or 38 to 42 
years should be asked to come back for testing after two 
years; people below that age of 16 or above the age of 
42 should be asked to come back after five years. In 
Zimbabwe the return times could be roughly twice as 
long. 
Conclusions 
In the early days of the HIV epidemic in southern Africa 
one could have argued that using a CD4+ threshold or a 
viral load threshold for deciding on when to start 
treatment was reasonable both for the individual person 
and as a way of triaging patients in favour of those most 
urgently in need of treatment. If one had been using a 
threshold based on CD4+ counts young adults should 
have been started on ART if their viral load was below 
about 400/μL in Botswana and 600/μL in South Africa. 
If one had been using a threshold based on viral load, 
young adults should have started treatment if their viral 
load was above 100k/mL in all countries. The early IAS 
criteria for deciding when to start treatment were about 
right for young people. 
 The epidemics of HIV are now mature and the 
situation has changed. For people aged 20 years one 
could consider delaying treatment using the same 
criteria as outlined early in the epidemic. However, it is 
now in the best interests of the patients to start ART 
immediately if they are more than 30 years old and 
found to be HIV-positive. Under these circumstances it 
would make most practical sense to start all HIV-
positive people on treatment immediately.65 The 
recommendations made by the World Health 
Organization between 2002 and 2009 (Figure 1) greatly  
reduced the number of people who were eligible for 
treatment. 
 Although they are not included in this study, a group 
of people who are of particular concern are those 
children who are infected vertically and survive for 
more than two years after which their life-expectancy is 
about 16 years.65 However, it is clear that if they are not 
started on treatment immediately they are unlikely to 
develop normally, either physically or mentally, and 
they must be started on ART as early as possible. 
 It is important to decide on the frequency with which 
people should be retested especially in settings where 
the prevalence is low. For example, based on data from 
women attending ante-natal clinics, the prevalence of 
infection among low risk women in Vietnam is about 
0.3% and for every 1,000 women tested only 3 would be 
found to have HIV. For such women active case-finding 
would be expensive but passive case finding and 
provider initiated testing would be appropriate. Since 
the prevalence of infection among such women must be 
about 0.03% per year one might argue that if they are 
found to be HIV-negative their chance of becoming 
infected in the next ten twenty years, say, would still be 
less than 1% and they need not be retested unless of 
course they have an infected partner or reason to believe 
that they may have been exposed to HIV. 
 This analysis suggests that given the current state of 
HIV in southern Africa it is in the best interests of the 
individual person to start treatment as soon as they are 
found to be HIV positive and that neither CD4+ cell 
counts nor viral load tests will significantly help to 
decide on whom to treat. The added benefits to the 
individual of avoiding the deterioration of their immune 
system which starts as soon as they have become 
infected as well as the very substantial reduction in the 
likelihood that they will infect their sexual 
partners22,66,67 provides even greater urgency to the need 
to start treatment as soon as people are found to be HIV-
positive. 
 The most important unknown in the model to assess 
the impact of using viral load tests for deciding when to 
start treatment concerns the relationship between 
survival and viral load. It is thought that both are good 
predictors of life-expectancy after infection but there are 
few data that help us to understand the relationship 
between set-point viral load and age as predictors of 
survival. 
 We show in this paper that if we are concerned to 
‘do no harm’ then the use of CD4+ cell counts or viral 
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load testing should be abandoned. If we also take into 
account the now accepted fact that the HIV-virus begins 
to compromise ones immune system from within weeks 
of infection, that the immune function, even with the 
best available drugs, shows significantly less recovery if 
one starts treatment later,23 the increase in mortality 
even among those with very high CD4+ cell counts, the 
very substantial evidence that early treatment stops 
transmission,19,22,68 and the cost and social savings that 
will undoubtedly accrue from early treatment,34,36 then 
regular testing and early treatment should now be made 
the standard of care. 
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